Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
Completed · Phase 1
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temozolomide may also help VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug. Giving temozolomide together with VNP40101M may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide and VNP40101M in treating patients with relapsed or refractory leukemias.
Key facts
- Study ID
- NCT00098436
- Run by
- Vion Pharmaceuticals
- People needed
- 25
- Starts
- 2004-09-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2013-07-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- American Health Network - North Illinois Street — Indianapolis, Indiana, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.